BioShockers 1Q 2010 Watch List
ANX (.3499) – NDA Submission for ANX-530 by mid-January.
CRXX (0.83) – FDA Decision on Exalgo on Feb. 22.
DDSS (2.08) – FDA Decision on novel formulation of Trazadone on Feb. 11.
IGXT.OB (0.62) – FDA Decision on higher dosage of Welbutrin on Feb. 6.
IVD (0.51) – Possible FDA Decision for the MAGO® 4S 510k submission in 1Q 2010.
BNVI (0.4755) – Possible initiation of 1st of two pivotal phase 3 trials for Menerba.
GNVC (1.18) – Possible release of PACT trial data.
NEXM (0.285) - 1Q financials, since Bio-Quant acquisition completed Dec. 2009.
ACHN (3.11) - Possible early-mid January release of an additional cohort's data in their Hepatitis C drug.
Possible BioShockers, but w/ higher level of risk than others:
CDXP.OB (0.05) – Note due, but note holders keep extending due date. In my opinion, partnership could possibly be coming. But, it is also very likely that they file for BK.
GLTA!
Disclosure: Do your OWN DD before investing. Do not buy or sell securities based on my nor anyone else's opinion.
Visit my biotech investing board!: investorshub.advfn.com/boards/board.aspx?board_id=16653
GLTA.
